Segment Reporting by business sector Audited

XLS

 

Merck Serono

Consumer
Health Care

Pharmaceuticals

Group/
Continuing Operations

€ million

2008

2007

2008

2007

2008

2007

2008

2007

*

including Discontinued operations

Sales

4,649.6

4,187.0

439.9

418.2

5,089.5

4,605.2

7,201.6

6,775.1

Royalty income

337.2

270.7

1.8

1.5

339.0

272.2

356.4

282.0

Total revenues

4,986.8

4,457.7

441.7

419.7

5,428.5

4,877.4

7,558.0

7,057.1

Gross margin

4,191.3

3,764.7

293.7

283.7

4,485.0

4,048.4

5,652.0

5,277.3

Selling. general and administration

–1,958.9

–1,980.9

–213.4

–210.0

–2,172.3

–2,190.9

–2,712.9

–2,717.1

Research and development

–1,074.4

–878.6

–16.8

–12.0

–1,091.2

–890.6

–1,234.4

–1,027.7

Operating result

593.7

356.9

61.3

59.6

655.0

416.5

1,131.4

976.0

Exceptional items

–354.0

–743.6

–354.0

–743.6

–400.0

–775.6

Earnings before interest and tax (EBIT)

239.7

–386.7

61.3

59.6

301.0

–327.1

731.4

200.4

Net operating assets

10,355.9

9,884.8

325.9

281.0

10,681.8

10,165.8

12,768.2

12,179.9

Segment liabilities

–972.1

–799.0

–62.6

–54.5

–1,034.7

–853.5

–1,316.7

–1,128.0

Capital spending on property. plant and equipment

235.4

147.6

14.1

6.1

249.5

153.7

394.7

263.3

Investments in intangible assets

123.2

91.7

2.4

0.8

125.6

92.5

140.9

101.6

Net cash flows from operating activities

926.8

875.9

45.6

50.9

972.4

926.8

1,024.0

1,181.4

Net cash flows from investing activities

–373.1

–7,381.0

–40.0

–4.0

–413.1

–7,385.0

–81.7

–7,525.4

Free cash flow*

553.8

–6,505.1

5.6

46.9

559.4

–6,458.2

438.4

–1,473.1

Impairment losses

–338.8

–100.2

–338.8

–100.2

–345.6

–109.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liquid Crystals

Performance &
Life Science Chemicals

Chemicals

Group/
Continuing Operations

in Mio €

2008

2007

2008

2007

2008

2007

2008

2007

Sales

864.6

909.4

1,240.9

1,231.3

2,105.5

2,140.7

7,201.6

6,775.1

Royalty income

12.3

6.3

5.1

3.5

17.4

9.8

356.4

282.0

Total revenues

876.9

915.7

1,246.0

1,234.8

2,122.9

2,150.5

7,558.0

7,057.1

Gross margin

540.6

611.3

629.1

615.1

1,169.7

1,226.4

5,652.0

5,277.3

Selling. general and administration

–61.4

–42.5

–401.4

–409.9

–462.8

–452.4

–2,712.9

–2,717.1

Research and development

–84.8

–78.8

–58.4

–58.3

–143.2

–137.1

–1,234.4

–1,027.7

Operating result

391.2

486.6

166.5

144.4

557.7

631.0

1,131.4

976.0

Exceptional items

–46.0

–46.0

–400.0

–775.6

Earnings before interest and tax (EBIT)

391.2

486.6

120.5

144.4

511.7

631.0

731.4

200.4

Net operating assets

944.3

915.1

1,127.7

1,053.0

2,072.0

1,968.1

12,768.2

12,179.9

Segment liabilities

–98.2

–90.0

–173.6

–176.9

–271.8

–266.9

–1,316.7

–1,128.0

Capital spending on property. plant and equipment

64.5

48.6

78.9

57.9

143.4

106.5

394.7

263.3

Investments in intangible assets

2.0

1.5

3.4

7.5

5.4

9.0

140.9

101.6

Net cash flows from operating activities

472.7

474.0

146.5

181.1

619.2

655.1

1,024.0

1,181.4

Net cash flows from investing activities

–70.6

–49.2

–88.8

–49.3

–159.4

–98.5

–81.7

–7,525.4

Free cash flow*

402.1

424.8

57.7

131.8

459.8

556.6

438.4

–1,473.1

Impairment losses

–0.6

–0.2

–6.1

–8.9

–6.7

–9.1

–345.6

–109.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate
and Other

Discontinued
Operations (Generics)

Reversal Discontinued
Operations (Generics)

Group/
Continuing Operations

in Mio €

2008

2007

2008

2007

2008

2007

2008

2007

Sales

6.6

29.2

1,391.8

–1,391.8

7,201.6

6,775.1

Royalty income

2.7

–2.7

356.4

282.0

Total revenues

6.6

29.2

1,394.5

–1,394.5

7,558.0

7,057.1

Gross margin

–2.7

2.5

656.8

–656.8

5,652.0

5,277.3

Selling. general and administration

–77.8

–73.8

–364.6

364.6

–2,712.9

–2,717.1

Research and development

–95.3

95.3

–1,234.4

–1,027.7

Operating result

–81.3

–71.5

188.7

–188.7

1,131.4

976.0

Exceptional items

–32.0

3,561.5

–3,561.5

–400.0

–775.6

Earnings before interest and tax (EBIT)

–81.3

–103.5

3,750.2

–3,750.2

731.4

200.4

Net operating assets

14.4

46.0

19.4

–19.4

12,768.2

12,179.9

Segment liabilities

–10.2

–7.6

–7.5

7.5

–1,316.7

–1,128.0

Capital spending on property. plant and equipment

1.8

3.1

19.5

–19.5

394.7

263.3

Investments in intangible assets

9.9

0.1

19.5

–19.5

140.9

101.6

Net cash flows from operating activities

–567.6

–400.5

36.9

–36.9

1,024.0

1,181.4

Net cash flows from investing activities

490.8

–41.9

4,797.9

–4,797.9

–81.7

–7,525.4

Free cash flow*

–580.8

–406.3

4,834.8

438.4

–1,473.1

Impairment losses

–0.1

–345.6

–109.3